Frazis Capital Podcast

Clarity Pharmaceuticals Success: Clarity Pharmaceuticals reported a significant response in a patient with metastatic castrate-resistant prostate cancer. The patient received two cycles of copper 67 Biss. PSMA, and after six months from the second dose, there was no evidence of PSA, indicating a potential cure. This is noteworthy because the patient had undergone extensive prior treatments, including chemotherapy and androgen deprivation therapy. Trial Progress and Market Potential: Clarity Pharmaceuticals has been releasing data as each cohort progresses in their trial, currently in the fourth cohort of phase one. The market potential for effective prostate cancer treatment is significant, estimated at over $6 billion. The company's stock is trading at around $650 million, with considerable interest from both investors and pharmaceutical companies due to the promising trial results. Director Confidence and Financials: Directors have shown confidence in the company by purchasing